Investigational Gout Drugs Do Well in Clinical Trials
Two major American drug companies are racing to get rival new gout medications to market. Both gout medicines take novel approaches to treating refractory gout - gout that hasn't already responded well to be able to current treatment.
Ardea Biosciences had been the first to announce productive clinical trials of its experimental gout drug RDEA594, also called Lesinurad. Lesinurad's mechanism of action is different from that of the commonly prescribed xanthine oxidase inhibitors gout medications (such as allopurinol and febuxostat), which decrease the development of uric acid.
Lesinurad is often a URAT1 transporter inhibitor which boosts reduction of uric acid through the kidneys. Lesinurad is also active towards another important regulator of urate secretion, OAT4. OAT4 is thought to be responsible for the high uric acid levels in gouty arthritis patients whose condition is caused or worsened by diuretics.
The Lesinurad study involved 208 gout patients who had high blood urate levels for at least A few months, even while taking the gout drug allopurinol. Individuals continued on allopurinol and were randomly assigned to receive either a placebo or lesinurad at doses of 200 mg, 400 mg, or 600 mg for four weeks.
All three groups who were given lesinurad confirmed substantially lower uric acid levels at the conclusion of the month. The percentage of patients who achieved the target for uric acid levels after treatment was 28% in the placebo group, 71% in the 200 mg team, 76% in the 400 mg group, and 87% in the 600 mg group.
More not too long ago, shares of BioCryst Pharmaceuticals rose 12% upon the release of the results of its phase 2b randomized, double-blind, study with the investigational gout drug BCX4208. BCX4208 is often a novel enzyme inhibitor that acts upstream of xanthine oxidase in the purine metabolism path to reduce serum uric acid (sUA).
Its mechanism of action complements xanthine oxidase inhibitors like allopurinol as well as febuxostat in reducing uric acid production, and BCX4208 is intended as an add-on therapy for those gouty osteoarthritis patients who do not respond well in order to current gout medication.
Like Lesinurad, BCX4208 was studied in gouty arthritis patients who had experienced high blood urate levels for at least 6 months, despite taking the gout drug allopurinol. The 279 study participants were randomly assigned to take BCX4208 at doses of possibly 5 mg, 10 mg, 20 mg, or 40 mg once daily for 12 weeks. One group of individuals was given a placebo. All participants were also given allopurinal 300 mg once-daily.
- All but one of the doses showed that BCX4208 was superior to the placebo when taken with allopurinol.
- The BCX4208 doses looked at in the study showed response rates ranging from 33% to 49%, compared to 18% for those taking the placebo.
At this point, Lesinurad appears the more promising of the two gout drugs, and the most likely to hit the market first. That outperformed BCX4208 in early clinical trials, and is farther forward in the development and approval process. But individual responses in order to drugs vary, and gout patients will benefit from having two new approaches to relieving the symptoms of this painful condition.
Gout: Treatment, Causes, Massage Therapy, Prevention
Gout frequently affects the big toe in the foot. Massage therapy focused at the big toe nail helps in decreasing pain and swelling. Know its causes, symptoms, ...
Alex Ray Advocates With Regard to Affordable Access to Healthcare and Medication
She recommends Big Mountain Drugs as a trusted on the internet Canadian pharmacy from which to buy allopurinol and colchicine for gout. For more information about gout and gout medication, go to the online resource www.colchicine.ca.
Susie is a leading curator at omex3.com, a resource about alternative natural health. Last year, Susie worked as a post curator at a well-known tech web site. When she's not sourcing web posts, Susie enjoys working out and skateboarding.